Mac-1 expression and binding of either anti-MPO or anti-OVA by circulating neutrophils in untreated wild-type and MPO−/− mice
| Population . | Proportion of total neutrophils . | M1/70 MFI . | % +ve for anti-OVA or anti-MPO . | Anti-MPO MFI . |
|---|---|---|---|---|
| Wild-type + anti-OVA, n = 8 | ||||
| Gr-1hi/M1/70int | All | 81 ± 8 | 0.3% ± 0.1% (anti-OVA+ve) | — |
| Wild-type + anti-MPO, n = 8 | ||||
| Gr-1hi/M1/70int | 84% ± 18% | 78 ± 17 | 32% ± 5% (anti-MPO+ve) | 9.5 ± 1.3 |
| Gr-1lo/M1/70hi | 16% ± 20% | 326 ± 48 | 95% ± 4% (anti-MPO+ve) | 31.9 ± 1.8 |
| MPO−/− + anti-MPO, n = 4 | ||||
| Gr-1int/M1/70int | 97% ± 3% | 64 ± 14 | 2% ± 1%, (anti-MPO+ve) | 4 ± 0.5 |
| Population . | Proportion of total neutrophils . | M1/70 MFI . | % +ve for anti-OVA or anti-MPO . | Anti-MPO MFI . |
|---|---|---|---|---|
| Wild-type + anti-OVA, n = 8 | ||||
| Gr-1hi/M1/70int | All | 81 ± 8 | 0.3% ± 0.1% (anti-OVA+ve) | — |
| Wild-type + anti-MPO, n = 8 | ||||
| Gr-1hi/M1/70int | 84% ± 18% | 78 ± 17 | 32% ± 5% (anti-MPO+ve) | 9.5 ± 1.3 |
| Gr-1lo/M1/70hi | 16% ± 20% | 326 ± 48 | 95% ± 4% (anti-MPO+ve) | 31.9 ± 1.8 |
| MPO−/− + anti-MPO, n = 4 | ||||
| Gr-1int/M1/70int | 97% ± 3% | 64 ± 14 | 2% ± 1%, (anti-MPO+ve) | 4 ± 0.5 |
Data are shown as mean ± SEM.
— indicates not applicable.